KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Income from Continuing Operations rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Income from Continuing Operations stood at $175.2 million for Q3 2025, which was up 6.11% from $165.1 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Income from Continuing Operations ranged from a high of $216.6 million in Q3 2021 and a low of $22.7 million during Q2 2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was $93.2 million (2024), whereas its average is $107.6 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Income from Continuing Operations skyrocketed by 557.07% in 2021, and later tumbled by 75.20% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Income from Continuing Operations stood at $66.8 million in 2021, then declined by 13.58% to $57.7 million in 2022, then spiked by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then climbed by 27.89% to $175.2 million in 2025.
  • Its Income from Continuing Operations stands at $175.2 million for Q3 2025, versus $165.1 million for Q2 2025 and $118.1 million for Q1 2025.